Literature DB >> 23956137

Increasing trends in Schedule II opioid use and doctor shopping during 1999-2007 in California.

Huijun Han1, Philip H Kass, Barth L Wilsey, Chin-Shang Li.   

Abstract

PURPOSE: To examine the age and gender-specific trends of Schedule II opioid use among California residents, with special reference to multiple provider users (doctor shoppers).
METHODS: Utilizing data from the California Prescription Drug Monitoring Program, we examined age and gender-specific trends of Schedule II opioid use during calendar years 1999-2007. Specifically, we analyzed the following: (1) the prevalence of Schedule II opioid users among California's population and (2) the proportion of these opioid users who were doctor shoppers (defined as an individual who used more than five different prescribers for all Schedule II opioids he or she obtained in a calendar year).
RESULTS: Among all age and gender groups, the prevalence of Schedule II opioid users in California increased by 150%-280% and the prevalence of doctor shoppers among users increased by 111%-213% over 9 years. The prevalence of opioid users was lowest among 18-44 year old men (1.25%) and highest among 65-year and older women (5.31%) by 2007. The prevalence of doctor shoppers was approximately 1.4% among those up to age 64 years and 0.5% among those 65 years and older. The gender difference in doctor shoppers among all age groups was negligible. On average, the cumulative morphine-equivalent amount of Schedule II opioid per individual obtained per year was threefold to sixfold higher for doctor shoppers than for the general population across different age and gender groups.
CONCLUSIONS: Age and gender differences in opioid use were relatively small, whereas the trends for use of opioids and multiple providers grew at a disquieting rate.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  California; age; doctor shopping; gender; opioid prescription; pharmacoepidemiology; prevalence

Mesh:

Substances:

Year:  2013        PMID: 23956137      PMCID: PMC3947314          DOI: 10.1002/pds.3496

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  22 in total

1.  Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential.

Authors:  L Simoni-Wastila; C Tompkins
Journal:  Subst Use Misuse       Date:  2001 Jul-Aug       Impact factor: 2.164

2.  The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society.

Authors: 
Journal:  Clin J Pain       Date:  1997-03       Impact factor: 3.442

3.  Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section.

Authors: 
Journal:  Anesthesiology       Date:  1997-04       Impact factor: 7.892

4.  Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data.

Authors:  Stephen T Parente; Susan S Kim; Michael D Finch; Lisa A Schloff; Thomas S Rector; Raafat Seifeldin; J David Haddox
Journal:  Am J Manag Care       Date:  2004-11       Impact factor: 2.229

5.  Opioid dosing trends and mortality in Washington State workers' compensation, 1996-2002.

Authors:  Gary M Franklin; Jaymie Mai; Thomas Wickizer; Judith A Turner; Deborah Fulton-Kehoe; Linda Grant
Journal:  Am J Ind Med       Date:  2005-08       Impact factor: 2.214

6.  Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study.

Authors:  Jennifer Brennan Braden; Ming-Yu Fan; Mark J Edlund; Bradley C Martin; Andrea DeVries; Mark D Sullivan
Journal:  J Pain       Date:  2008-07-26       Impact factor: 5.820

7.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

8.  Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study.

Authors:  Mark D Sullivan; Mark J Edlund; Ming-Yu Fan; Andrea DeVries; Jennifer Brennan Braden; Bradley C Martin
Journal:  Pain       Date:  2008-06-10       Impact factor: 6.961

9.  Patterns of abuse among unintentional pharmaceutical overdose fatalities.

Authors:  Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

10.  Individual and county-level factors associated with use of multiple prescribers and multiple pharmacies to obtain opioid prescriptions in California.

Authors:  Huijun Han; Philip H Kass; Barth L Wilsey; Chin-Shang Li
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more
  11 in total

1.  Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California.

Authors:  Joseph Friedman; David Kim; Todd Schneberk; Philippe Bourgois; Michael Shin; Aaron Celious; David L Schriger
Journal:  JAMA Intern Med       Date:  2019-04-01       Impact factor: 21.873

Review 2.  Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.

Authors:  Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

3.  Overdose Risk and Acquiring Opioids for Nonmedical Use Exclusively from Physicians in Vancouver, Canada.

Authors:  Tessa Cheng; Will Small; Ekaterina Nosova; Robert Hogg; Kanna Hayashi; Thomas Kerr; Kora DeBeck
Journal:  Subst Use Misuse       Date:  2020-06-26       Impact factor: 2.164

4.  Use of opioids and other analgesics by older adults in the United States, 1999-2010.

Authors:  Michael A Steinman; Kiya D R Komaiko; Kathy Z Fung; Christine S Ritchie
Journal:  Pain Med       Date:  2014-10-28       Impact factor: 3.750

5.  Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities.

Authors:  Bradley D Stein; Joshua Mendelsohn; Adam J Gordon; Andrew W Dick; Rachel M Burns; Mark Sorbero; Regina A Shih; Rosalie Liccardo Pacula
Journal:  J Addict Dis       Date:  2016-07-22

6.  Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Authors:  Célian Bertin; Jessica Delorme; Marie Riquelme; Hélène Peyrière; Georges Brousse; Alain Eschalier; Denis Ardid; Chouki Chenaf; Nicolas Authier
Journal:  Br J Clin Pharmacol       Date:  2019-08-24       Impact factor: 4.335

7.  A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain.

Authors:  Beatrice Setnik; Carl L Roland; Kenneth W Sommerville; Glenn C Pixton; Robert Berke; Anne Calkins; Veeraindar Goli
Journal:  J Pain Res       Date:  2015-07-09       Impact factor: 3.133

Review 8.  The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse.

Authors:  Charles P Schaefer; Margaret E Tome; Thomas P Davis
Journal:  Fluids Barriers CNS       Date:  2017-11-29

9.  Identifying and classifying opioid-related overdoses: A validation study.

Authors:  Carla A Green; Nancy A Perrin; Brian Hazlehurst; Shannon L Janoff; Angela DeVeaugh-Geiss; David S Carrell; Carlos G Grijalva; Caihua Liang; Cheryl L Enger; Paul M Coplan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-04-24       Impact factor: 2.890

10.  Evaluating Opioid Dispensing Rates among Pediatrics and Young Adults based on CURES Data Reporting in California from 2015-2019.

Authors:  Michael T Phan; Courtney Wong; Daniel M Tomaszewski; Zeev N Kain; Brooke Jenkins; Candice Donaldson; Michelle Fortier; Sun Yang
Journal:  J Contemp Pharm Prac       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.